Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial

Documenti analoghi

• Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial‐onset seizures: A randomized historical‐control phase III study based in North America
  di: Sperling, Michael R., et al.
  Pubblicazione: (2015)
• Incidence of seizure exacerbation and seizures reported as adverse events during adjunctive treatment with eslicarbazepine acetate: A pooled analysis of three Phase III controlled trials
  di: Carreño, Mar, et al.
  Pubblicazione: (2017)
• Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study
  di: Jacobson, Mercedes P, et al.
  Pubblicazione: (2015)
• Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures
  di: Costa, Raquel, et al.
  Pubblicazione: (2018)
• Safety and Tolerability of Adjunctive Eslicarbazepine Acetate in Pediatric Patients (Aged 4-17 Years) With Focal Seizures
  di: Mintz, Mark, et al.
  Pubblicazione: (2019)